Jansen Potash Stage 2 capex revised up ~40% to US$6.9bn (vs. GSe US$6.5bn) and to proceed on current schedule

Research evidence excerpt

Jansen Potash Stage 2 capex revised up ~40% to US$6.9bn (vs. GSe US$6.5bn) and to proceed on current schedule

h Floor, Ascent-Worli, Sudam Kalu Ahire Marg, Worli, Mumbai-400 025, India, Corporate

Identity Number U74140MH2006FTC160634, Phone +91 22 6616 9000, Fax +91 22 6616 9001. Goldman Sachs may beneficially own 1% or more of

the securities (as such term is defined in clause 2 (h) the Indian Securities Contracts (Regulation) Act, 1956) of the subject company or companies

referred to in this research report. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to

investors. Goldman Sachs (India) Securities Private Limited compliance officer and investor grievance contact details can be found at:

https://www.goldmansachs.com/worldwide/india/documents/Grievance-Redressal-and-Escalation-Matrix.pdf, and a copy of the annual audit

compliance report can be found at this link: https://publishing.gs.com/content/site/india-annual-compliance-report.html. Japan: See below. Korea:

This research, and any access to it, is intended only for “professional investors” within the meaning of the Financial Services and Capital Markets Act,

unless otherwise agreed by Goldman Sachs. Further information on the subject company or companies referred to in this research may be obtained

from Goldman Sachs (Asia) L.L.C., Seoul Branch. New Zealand: Goldman Sachs New Zealand Limited and its affiliates are neither “registered banks” nor

“deposit takers” (as defined in the Reserve Bank of New Zealand Act 1989) in New Zealand. This research, and any access to it, is intended for